Tyrosine kinase inhibitorFDA-approvedFirst-line
Tafinlar + Mekinist
Generic name: dabrafenib + trametinib
How it works
Blocks the BRAF V600E mutation and the MEK protein, which are involved in cancer cell growth, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E-positive
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median progression-free survival of approximately 11.4 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.